Activation of PIK3CA mutations and deletion of PTEN (PTEN is a key negative regulator of PI3K signaling) lead to resistance to trastuzumab and lapatinib in breast cancer cell lines, and low PTEN levels are associated with worse patient prognosis (20–22). The gene discussed is PIK3CA; the disease is breast carcinoma.